Traci McCarty | VP, IR |
Jean-Jacques Bienaimé | Chairman and CEO |
Greg Guyer | EVP and Chief Technical Officer |
Jeff Ajer | EVP and CCO |
Henry Fuchs | President, Worldwide Research and Development |
Brian Mueller | EVP, CFO |
Salveen Richter | Goldman Sachs |
Cory Kasimov | JPMorgan |
Robyn Karnauskas | SunTrust Securities |
Chris Raymond | Piper Sandler |
Martin Auster | Credit Suisse |
Paul Matteis | Stifel |
Philip Nadeau | Cowen and Company |
Geoff Meacham | Bank of America Merrill Lynch |
Akash Tewari | Wolfe Research |
Matthew Harrison | Morgan Stanley |
Gena Wang | Barclays |
Gershell Leland | Oppenheimer |
Ladies and gentlemen, thank you for standing-by and welcome to the BioMarin Third Quarter 2020 Financial Results Conference Call. Hosting the conference call today is from BioMarin, Traci McCarty, Vice President of Investor Relations. Please go ahead madam.
Thank you, Joana, and thank you all for joining us today. To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin’s financial performance, commercial products and potential future products in different areas of therapeutic research and development.